期刊文献+

鼻咽癌表皮生长因子受体研究现状

Research advances of EGFR in nasopharyngeal cancer
原文传递
导出
摘要 近年来的许多研究表明表皮生长因子受体(EGFR)的表达与鼻咽癌的生物学行为及预后密切相关。鼻咽癌EGFR的表达与鼻咽癌的分期呈正相关,与近期疗效及远期预后呈负相关。在鼻咽癌的发展过程中,EGFR与环氧化酶2(COX-2),潜伏膜蛋白-1(LMP-1)相互协同而发挥作用。抗EGFR治疗有望提高疗效,改善预后。 Many research results proved that there is closely relationship between expression of EGFR and biological behavior and prognosis of NPC. There is a positive correlation between expression of EGFR and stage of NPC, but negative correlation with prognosis of NPC. During the course of development of NPC, EGFR act collaboratively with LMP-1 and COX-2.
出处 《肿瘤研究与临床》 CAS 2011年第12期855-858,共4页 Cancer Research and Clinic
关键词 鼻咽肿瘤 受体 表皮生长因子 环氧化酶2 潜伏膜蛋白1 Nasopharyngeal neoplasms Receptor, epidermal growth factor Cyclooxygenase 2 Latent membrance protein 1
  • 相关文献

参考文献4

二级参考文献55

  • 1郑唯强,倪灿荣,龚志锦,李全华,詹洲.乳腺癌上皮生长因子受体的临床病理观察及预后意义[J].癌症,1995,14(1):19-20. 被引量:3
  • 2许良中,郑颂国,朱伟萍,张秦明.EGFR与C-erbB-2癌基因蛋白在甲状腺乳头状腺癌中的表达[J].实用癌症杂志,1995,10(2):102-104. 被引量:4
  • 3康小伟.Ras蛋白与信号传导[J].生命科学,1996,8(2):24-26. 被引量:11
  • 4袁志忠,叶挺军,陈泳莲.脑胶质瘤表皮生长因子受体表达及其意义[J].中华病理学杂志,1996,25(6):369-370. 被引量:3
  • 5李彦锋,方玉华,李黔生,邓晓洪,江军.癌性及良性增生前列腺组织中表皮生长因子受体的研究[J].中华实验外科杂志,1997,14(1):30-30. 被引量:4
  • 6[1]Ranson M. ZD1839 (IRESSA): For more than just non-small cell lung cancer [J]. The Oncologist, 2002, 7(suppl 4): 16 - 24.
  • 7[2]Ciardiello F, Caputo R, Bianco R, et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor [J]. Clin Cancer Res, 2000, 6(5):2053 - 2063.
  • 8[3]Ciardiello F, Caputo R, Bianco R, et al. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839(Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor [J]. Clin Cancer Res, 2001, 7(5): 1459 - 1465.
  • 9[4]Baselga J, Rischin D, Ranson M, et al. Phase Ⅰ safety,pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types [J] . J Clin Oncol, 2002, 20(21 ): 4292 - 4302.
  • 10[5]Herbst RS, Maddox AM, Rothenberg ML, et al. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839is well-tolerrated and has activity in non-small-cell lung cancer and other solid tumors: results on a phase Ⅰ trial [J]. J Clin Oncol,2002, 20( 18): 3815 - 3825.

共引文献44

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部